Synapse Biomedical Inc. Receives CE Approval for TransAeris, the First Medical Device Approved for the Treatment of Ventilator Induced Diaphragm Dysfunction (VIDD)
About TransAeris technology
The TransAeris™ System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD). TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to treat VIDD. Once the patient is successfully extubated after mechanical ventilation, the electrodes are removed from the patient.
About Synapse Biomedical, Inc.
Founded in 2002, Synapse Biomedical's mission is to provide life transforming treatments through the commercialization of neurostimulation platforms and build a sustainable enterprise on the foundation of scientific & clinical findings that will provide meaningful value to patients, employees, community, and shareholders. Synapse is headquartered in Oberlin, Ohio and has a European Office in Enghien les Bains, France. For more information please visit www.synapsebiomedical.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108005174/en/
Website: http://www.synapsebiomedical.com
Contact
Synapse Biomedical Europe
Moustapha Diop
COO & Managing Director
+33 (0)6 11 67 53 46
mdiop@synapsebiomedical.com
This news is a press release provided by Synapse Biomedical, Inc..